July 15, 2020
At a time when access, health justice and equity are uppermost for us all, AVAC is pleased to offer a new advocates’ guide to long-acting injectable PrEP, a new prevention strategy that’s shown benefit in some populations and generated a lot of buzz recently.
Want to know what’s known and unknown, who should do what, and what you can do? Click here to read Understanding the Results of HPTN 083.
We’ve also created a webpage of resources for advocates seeking to learn more—click thru to listen to conversations with HPTN 083 and 084 researchers at the AIDS 2020 Research Literacy Networking Zone, learn more about the history of these trials of long-acting cabotegravir (CAB-LA), and more.
Also, save the date for a webinar, this Thursday, July 16, hosted by the HPTN where you can hear the primary results of HPTN 083 and ask all your burning questions! The call is at 10:30am EDT (visit www.worldtimebuddy.com for your local time zone) and dial-in information is here.
In the coming months, we will be convening with prevention research advocates to talk about critical next steps—for CAB-LA and for prevention generally. At AVAC, we will be working to ensure that development and introduction of new PrEP strategies expands equitable access to existing daily oral PrEP, with multi-month prescriptions and self-testing where feasible, to support continued use in COVID-19 contexts. We need your help to advance primary prevention and research agendas that leave no one behind. Join us!